JAAD online
Eccrine squamous syringometaplasia associated with dabrafenib therapy

https://doi.org/10.1016/j.jaad.2013.06.049Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (9)

  • Encorafenib-induced eccrine squamous syringometaplasia

    2024, Annales de Dermatologie et de Venereologie
  • Cutaneous Adverse Reactions of Anticancer Agents

    2019, Dermatologic Clinics
    Citation Excerpt :

    NEH due to BRAFi does not seem to recur on switching to an alternative BRAFi, and this can be used to manage NEH without compromising the chemotherapy regimen.21 Eccrine squamous syringometaplasia (ESS) is an uncommon cutaneous eruption characterized by erythematous macules, papules, and plaques that appear about 2 to 30 days after starting chemotherapy.24,25 A case series observed the bilaterally symmetric intertriginous pattern to be the most common presentation.

  • Sorafenib-induced eccrine squamous syringometaplasia

    2022, Australasian Journal of Dermatology
View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: None declared.

View full text